Pharma Equipment Major Cytiva Opens New $3 Million Facility in Pune

Pharmaceutical equipment giant Cytiva, previously known as GE Lifesciences and currently owned by the Washington-based Danaher Corporation, has recently inaugurated a new facility in Pune. With an investment of approximately USD 3 million, this addition to the company's infrastructure is set to double its production capacity from 75 to 150 projects. The unique measure of capacity in terms of 'projects' is due to the fact that a single order often comprises multiple pieces of equipment.

Expanding Capacity

Rajan Shankaran, the head of Cytiva India, shared that this new unit will primarily be responsible for assembling various products rather than manufacturing them outright. This assembly line approach will allow for increased efficiency and output. Spanning over an expansive area of 33,000 sq ft within the Rajiv Gandhi Infotech Park in Hinjenwadi, Pune, this facility is designed to complement Cytiva's existing research and development centre located in Bengaluru which focuses on bioprocess discovery along with medical and genomic medicine businesses.

A Mix Of Local And Imported Components

The composition of components used at the new facility also reflects a blend between local sourcing and imports. According to Shankaran, around 35-40% components are sourced locally while the remaining majority comes from international suppliers. This mix ensures both quality control as well as cost-effectiveness.

Boosting Exports And Serving International Markets

The impact of this newly opened facility extends beyond domestic boundaries too. Once it reaches full capacity operationally, exports originating from this unit are projected to constitute about 30% of total production output. In terms of geographical reach, these exports are aimed towards markets including South Korea, Singapore and Australia thereby significantly enhancing Cytiva’s global presence.

The Growing Biopharma Equipment Market

The domestic biopharma and biosimilar equipment market in India is currently valued at around USD 500 million. With the establishment of this new facility, Cytiva will be well-equipped to cater to the growing demands within this sector while also potentially contributing towards its further expansion.

In conclusion, the opening of Cytiva's new facility in Pune represents a significant milestone for both the company as well as India's pharmaceutical industry. By doubling its capacity, sourcing locally-produced components and targeting international markets, Cytiva is setting itself up for continued growth and success. Furthermore, this development also signifies a positive trend towards increased investment within India's burgeoning biopharma equipment market which bodes well for future progress in this field.